Vicarious Surgical Inc Stock Price, News & Analysis

Vicarious Surgical (NYSE: RBOT) provided full‑year 2026 cash burn guidance of approximately $35 million, a $10 million improvement versus its updated 2025 guidance of $45 million. The company said cash needs beyond existing resources to achieve design freeze on the Vicarious Surgical system are approximately $25 million. Management attributed the improved guidance to an operational reset, including reductions in headcount and external consulting spend, partially offset by increased use of strategic outsourcing to meet critical development milestones. The company reiterated its target of achieving design freeze by year‑end 2026.

Vicarious Surgical (NYSE: RBOT) updated full-year 2025 financial guidance, now expecting cash burn of approximately $45 million, an improvement of $5 million from prior guidance of $50 million driven by disciplined cost management and an operational reset.

The company said it will provide full-year 2026 cash burn guidance before year-end to give investors visibility into the next phase. The Board also made committee appointments: Victoria Carr-Brendel as Compensation Committee chair, Fuad Ahmad to the Compensation Committee, and Joseph Doherty to the Audit Committee.

Vicarious Surgical (NYSE: WS) will participate in the Piper Sandler 37th Annual Healthcare Conference. Management is scheduled for a fireside discussion on Wednesday, December 3, 2025 at 4:30 PM ET. Interested parties can listen to a live audio webcast via the company’s investor site under Events & Presentations at the provided investor URL.

This announcement confirms the company’s investor outreach and provides the date, time, and webcast access for attendees and investors.

Vicarious Surgical (NYSE: RBOT, RBOT WS) reported third quarter 2025 results on November 12, 2025. The company reported total operating expenses of $11.5 million in Q3 2025, down 35% year-over-year, and a GAAP net loss of $11.1 million ($1.86 per share), improved from $17.1 million a year earlier. Management said it has begun implementation of a plan to reduce burn and reached design freeze progress.

The company raised $5.9 million in gross proceeds from a registered direct offering in October, held $13.4 million of cash and investments as of September 30, 2025, and recorded a Q3 cash burn of $10.5 million. Vicarious Surgical expects full-year 2025 cash burn of approximately $50 million. Management hosted a conference call on November 12, 2025.

Vicarious Surgical (NYSE: WS) will report financial results for the third quarter ended September 30, 2025 after market close on Wednesday, November 12, 2025.

Management will host a conference call beginning at 4:30 p.m. Eastern Time. Domestic callers may dial +1 833-470-1428, international callers +1 404-975-4839, using access code 623856. A live and archived webcast will be available at https://investor.vicarioussurgical.com.

Vicarious Surgical (NYSE: RBOT, RBOT WS) announced it will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host a conference call beginning at 4:30 p.m. Eastern Time the same day.

Investors can join by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) with access code 623856. A live and archived webcast will be available at https://investor.vicarioussurgical.com.

Vicarious Surgical (NYSE: RBOT) announced a registered direct offering and concurrent private placement expected to raise approximately $5.9 million gross proceeds. The company agreed to sell 1,150,000 shares of Class A common stock (or pre-funded warrants) at a combined effective price of $5.10 per share with accompanying warrants. Pre-funded warrants are priced at $5.0999. The private placement will issue Series A and Series B common warrants to purchase up to 1,150,000 shares each (total up to 2,300,000 shares) at a $5.10 exercise price, exercisable upon stockholder approval and expiring five years after approval. Series B warrants include a repurchase provision at $0.01 per underlying share upon specified stock-price/volume milestones. Lake Street Capital Markets is the placement agent. Closing expected on or about October 9, 2025, subject to customary conditions and NYSE authorization. Proceeds intended for general corporate purposes.

Vicarious Surgical (NYSE:RBOT) has appointed Joseph Doherty as Chairman of the Board of Directors. Doherty, who joined the board in June 2025, brings extensive healthcare and medical device industry experience, having served as CEO of Worcester City Campus Corporation and President of Scapa Healthcare.

His background includes leadership roles at Olympus Surgical Technologies America and a 24-year tenure at Johnson & Johnson, where he served as Vice President of Integration and Transformation. Doherty holds a BS in Engineering from West Point and an MBA from Nichols College.

Vicarious Surgical (NYSE:RBOT), a next-generation robotics technology company focused on transforming robotic surgery, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York.

The company's management team will deliver a presentation on Wednesday, September 10, 2025 at 9:00 a.m. ET. Investors and interested parties can access the live audio webcast through the Events & Presentations section of Vicarious Surgical's investor relations website.